Summary:
- Eli Lilly's revenue surged by 32% in 2024, thanks to strong demand for key drugs.
- Analysts predict significant upside potential with a one-year average price target of $1,016.77.
- The company's new partnership aims to bolster its cancer treatment offerings.
Eli Lilly and Company (LLY, Financial) has exhibited remarkable financial growth, achieving a 32% increase in annual revenue for 2024. This performance has outstripped its guidance by an impressive $4 billion, largely driven by heightened demand for its GLP-1 medications, Mounjaro and Zepbound. Additionally, a strategic partnership with AdvanCell seeks to broaden its cancer treatment portfolio, a move that could further enhance its market position.
Wall Street Analysts Forecast
The investment community has strong projections for Eli Lilly, with 25 analysts offering a one-year price target average of $1,016.77. The targets range widely, from a high estimate of $1,190.00 to a low of $800.00, suggesting a potential upside of 38.83% from its current price of $732.41. For a more comprehensive look at these estimates, visit the Eli Lilly and Co (LLY, Financial) Forecast page.
Furthermore, the consensus from 29 brokerage firms places Eli Lilly and Co (LLY, Financial) at an average recommendation of 1.9, indicative of an "Outperform" status on a scale where 1 signifies a Strong Buy and 5 denotes a Sell.
From a valuation standpoint, GuruFocus estimates the GF Value for Eli Lilly in one year to be $1126.33. This reflects a projected upside of 53.78% from the current trading price of $732.41. The GF Value represents GuruFocus's calculated fair value, considering historical trading multiples, past business growth, and future performance estimates. For further data and analysis, the Eli Lilly and Co (LLY, Financial) Summary page provides detailed insights.
